Free Trial

Aligos Therapeutics (ALGS) Competitors

Aligos Therapeutics logo
$10.44 +0.45 (+4.50%)
Closing price 10/20/2025 04:00 PM Eastern
Extended Trading
$10.20 -0.24 (-2.35%)
As of 10/20/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALGS vs. CRBU, TRDA, FHTX, PYXS, CLLS, EPRX, VOR, GNFT, CABA, and ACRS

Should you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Caribou Biosciences (CRBU), Entrada Therapeutics (TRDA), Foghorn Therapeutics (FHTX), Pyxis Oncology (PYXS), Cellectis (CLLS), Eupraxia Pharmaceuticals (EPRX), Vor Biopharma (VOR), GENFIT (GNFT), Cabaletta Bio (CABA), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.

Aligos Therapeutics vs. Its Competitors

Aligos Therapeutics (NASDAQ:ALGS) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Aligos Therapeutics presently has a consensus price target of $50.00, suggesting a potential upside of 378.93%. Caribou Biosciences has a consensus price target of $6.67, suggesting a potential upside of 136.41%. Given Aligos Therapeutics' higher possible upside, equities analysts plainly believe Aligos Therapeutics is more favorable than Caribou Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Caribou Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Aligos Therapeutics has a beta of 2.77, suggesting that its stock price is 177% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500.

Caribou Biosciences has a net margin of -1,800.93% compared to Aligos Therapeutics' net margin of -2,337.24%. Aligos Therapeutics' return on equity of -22.41% beat Caribou Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aligos Therapeutics-2,337.24% -22.41% -12.09%
Caribou Biosciences -1,800.93%-62.35%-49.65%

In the previous week, Aligos Therapeutics had 2 more articles in the media than Caribou Biosciences. MarketBeat recorded 4 mentions for Aligos Therapeutics and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.17 beat Aligos Therapeutics' score of 0.24 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aligos Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Caribou Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Aligos Therapeutics has higher earnings, but lower revenue than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos Therapeutics$3.94M16.30-$131.21M-$19.79-0.53
Caribou Biosciences$9.12M28.79-$149.10M-$1.78-1.58

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 4.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 8.3% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Caribou Biosciences beats Aligos Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Aligos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALGS vs. The Competition

MetricAligos TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$61.45M$3.46B$6.15B$10.56B
Dividend YieldN/A2.27%5.72%4.84%
P/E Ratio-0.5323.3929.4727.34
Price / Sales16.30483.15585.88238.70
Price / CashN/A45.2825.8230.35
Price / Book-1.3910.6112.526.69
Net Income-$131.21M-$52.56M$3.32B$276.46M
7 Day Performance8.07%3.95%1.80%-0.08%
1 Month Performance7.96%16.10%8.79%3.93%
1 Year Performance43.21%15.08%64.28%33.89%

Aligos Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALGS
Aligos Therapeutics
3.8946 of 5 stars
$10.44
+4.5%
$50.00
+378.9%
+44.0%$61.45M$3.94M-0.5390
CRBU
Caribou Biosciences
2.5545 of 5 stars
$2.38
-4.4%
$6.67
+180.1%
+41.0%$231.88M$9.99M-1.34100Gap Down
TRDA
Entrada Therapeutics
2.906 of 5 stars
$5.81
-4.6%
$25.67
+341.8%
-64.2%$231.65M$210.78M-3.26110
FHTX
Foghorn Therapeutics
2.5858 of 5 stars
$4.29
+5.7%
$11.00
+156.4%
-47.3%$229.51M$22.60M-3.61120
PYXS
Pyxis Oncology
2.8625 of 5 stars
$3.45
-6.8%
$7.75
+124.6%
-4.5%$229.47M$16.15M-2.1660
CLLS
Cellectis
2.1887 of 5 stars
$4.42
+9.4%
$4.00
-9.5%
+107.9%$224.56M$49.22M-5.39290Analyst Forecast
Gap Up
EPRX
Eupraxia Pharmaceuticals
2.631 of 5 stars
$6.05
-0.3%
$11.00
+81.8%
+134.3%$218.28MN/A-7.1229Short Interest ↑
VOR
Vor Biopharma
2.8819 of 5 stars
$32.29
+3.4%
$113.83
+252.5%
N/A$214.05MN/A-0.12140Insider Trade
Gap Up
GNFT
GENFIT
1.9534 of 5 stars
$4.25
flat
$7.00
+64.7%
-31.3%$212.52M$76.77M0.00120Positive News
CABA
Cabaletta Bio
2.7378 of 5 stars
$2.49
+7.3%
$13.44
+439.9%
-42.5%$212.20MN/A-0.9250Gap Up
ACRS
Aclaris Therapeutics
2.7468 of 5 stars
$1.91
+2.1%
$8.71
+356.2%
+68.9%$202.58M$18.72M-1.39100Positive News
Analyst Forecast
Analyst Revision
Gap Up

Related Companies and Tools


This page (NASDAQ:ALGS) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners